AxoGen Corporation (NASDAQ:AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
damage, today announced it will participate in the 99th Annual
Meeting of the American Association of Oral and Maxillofacial
Surgeons (AAOMS). The meeting, scheduled for October 9-14 at the
Moscone South Convention Center in San Francisco, attracts more
than 5,000 oral and maxillofacial surgeons, researchers, nurses,
students, and health care professionals from all over the world to
display, share and learn the advancements and innovations taking
place in the field of oral and maxillofacial (OMF) surgery and
dentistry.
“AxoGen’s comprehensive platform for nerve repair
includes solutions to address nerve damage in the jaw resulting
from either surgical injuries or reconstruction following benign
tumor removal or similar procedures,” said Karen Zaderej, president
and chief executive officer. “Recent clinical data has shown that
timely referral to a nerve repair specialist and repair of these
injuries with the AxoGen portfolio can provide meaningful recovery
in up to 94 percent of these patients. We are encouraged by
increased awareness of the AxoGen portfolio to assist surgeons in
improving the quality of life for patients with nerve damage.”
AxoGen is supporting a Hands-On Nerve
Repair Course: Numb Lip, Numb Tongue, Numb Chin and What to do
When on Thursday, October 12 from 8:00 a.m. to 12
noon in Room 159. The special session will provide
attendees with the opportunity to handle AxoGen products and gain a
better understanding of their use in oral and maxillofacial
applications.
In addition to the hands-on session, AxoGen will
talk with attendees and demo products at Booth
1708 on the exhibit floor. OMF surgeon thought leaders
will be available in the AxoGen booth at select times. These
experts will demonstrate surgical techniques for OMF nerve repair
and discuss the importance of timely referral pathways. Michael
Miloro, D.M.D., M.D., FACS will be at the AxoGen booth on Thursday,
October 12 from 12 noon until 1:00 p.m. John Zuniga, D.M.D., Ph.D.
will be at the AxoGen booth on Friday, October 13 from 3:00-4:00
p.m.
Other conference sessions featuring AxoGen’s
platform for nerve repair include Nerve Reconstruction for Patients
with Medication-related Osteonecrosis of the Jaw on Friday, October
13, and Updates in Trigeminal Nerve Microsurgery on Saturday,
October 14.
About AAOMSThe American
Association of Oral and Maxillofacial Surgeons (AAOMS), the
professional organization representing more than 9,000 oral and
maxillofacial surgeons in the United States, supports its members'
ability to practice their specialty through education, research and
advocacy. The mission of AAOMS is to assure excellence in patient
care by promoting, protecting and advancing the specialty of oral
and maxillofacial surgery, and the skill and professionalism of
AAOMS members.
About AxoGenAxoGen (AXGN) is a
global leader in innovative surgical solutions for peripheral nerve
injuries. AxoGen is the only company focused specifically on the
science, development and commercialization of technologies for
peripheral nerve regeneration and repair. We are passionate about
restoring nerve function and quality of life to patients with
peripheral nerve injuries by providing innovative, clinically
proven and economically effective repair solutions for surgeons and
health care providers. Peripheral nerves provide the pathways for
both motor and sensory signals throughout the body. Every day,
people suffer traumatic injuries or undergo surgical procedures
that impact the function of their peripheral nerves. Damage to
a peripheral nerve can result in the loss of muscle or organ
function, the loss of sensory feeling, or the initiation of
pain.
AxoGen's portfolio of products includes Avance®
Nerve Graft, an off-the-shelf processed human nerve allograft for
bridging severed nerves without the comorbidities associated with a
second surgical site, AxoGuard® Nerve Connector, a porcine
submucosa extracellular matrix (ECM) coaptation aid for tensionless
repair of severed nerves, AxoGuard® Nerve Protector, a porcine
submucosa ECM product used to wrap and protect injured peripheral
nerves and reinforce the nerve reconstruction while preventing soft
tissue attachments, and Avive® Soft Tissue Membrane, a
minimally processed human umbilical cord membrane that may be used
as a resorbable soft tissue covering to separate tissue layers and
modulate inflammation in the surgical bed. Along with these core
surgical products, AxoGen also offers AcroVal® Neurosensory &
Motor Testing System and AxoTouch® Two-Point Discriminator. These
evaluation and measurement tools assist health care professionals
in detecting changes in sensation, assessing return of sensory,
grip, and pinch function, evaluating effective treatment
interventions, and providing feedback to patients on nerve
function. The AxoGen portfolio of products is available in the
United States, Canada, the United Kingdom, and several other
European and international countries.
Cautionary Statements Concerning
Forward-Looking Statements This Press Release contains
"forward-looking" statements as defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations or predictions of future
conditions, events, or results based on various assumptions and
management's estimates of trends and economic factors in the
markets in which we are active, as well as our business plans.
Words such as "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "projects," "forecasts,"
"continue," "may," "should," "will," and variations of such words
and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our assessment on
our internal control over financial reporting, our growth, our 2017
guidance, product development, product potential, financial
performance, sales growth, product adoption, market awareness of
our products, data validation, our visibility at and sponsorship of
conferences and educational events. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect AxoGen's business
and its market, particularly those discussed in the risk factors
and cautionary statements in AxoGen's filings with the Securities
and Exchange Commission. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those projected. The forward-looking statements are
representative only as of the date they are made and, except as
required by law, AxoGen assumes no responsibility to update any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contact:AxoGen CorporationAnnette RuzickaCorporate
and Investor Communications763-458-4193aruzicka@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2024 to May 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From May 2023 to May 2024